Brain

Article	Citations
Correction to: Variants in the SK2 channel gene (KCNN2) lead to dominant neurodevelopmental movement disorders	450
Clinical and genetic characterization of a progressive RBL2-associated neurodevelopmental disorder	319
Choroid plexus mis-splicing and altered cerebrospinal fluid composition in myotonic dystrophy type 1	268
Source-sink connectivity: a novel interictal EEG marker for seizure localization	234
Somatic variants of MAP3K3 are sufficient to cause cerebral and spinal cord cavernous malformations	228
Peripherin is a biomarker of axonal damage in Guillain-Barré syndrome: a pathophysiological annotation	223
We’re all in this together: a rejoinder to Masud Husain’s (rant) editorial	213
Impaired ribosome-associated quality control of C9orf72 arginine-rich dipeptide-repeat proteins	212
Methodological drawbacks in the alleged association between foetal sonographic anomalies and autism	210
Reply: Is postural tachycardia syndrome a psychogenic disorder?; Notes on establishing fear conditioning as causal in the postural orthostatic tachycardia syndrome; Patients with POTS fear that data o	207
Thalamic stereo EEG: a clinically justified extension of hypothesis-driven intracranial exploration	193
Genetically identical twin-pair difference models support the amyloid cascade hypothesis	189
De novo variants in ATXN7L3 lead to developmental delay, hypotonia and distinctive facial features	180
In vivo self-assembled siRNAs ameliorate neurological pathology in TDP-43-associated neurodegenerative disease	176
The inferior fronto-occipital fasciculus: bridging phylogeny, ontogeny and functional anatomy	165
Cerebral amyloid angiopathy interacts with neuritic amyloid plaques to promote tau and cognitive decline	162
Associations between accelerated forgetting, amyloid deposition and brain atrophy in older adults	160
Global network and local vulnerabilities underlie brain atrophy across Parkinson’s disease stages	159
Diffusion MRI tracks cortical microstructural changes during the early stages of Alzheimer’s disease	153
Apathy, effort-based decisions and brain integrity in Alzheimer's and Parkinson's diseases	153
‘Hippocampal innate inflammatory gliosis only’ in pharmacoresistant temporal lobe epilepsy	151
Maternal microbiome-derived propionate regulates offspring myelination via histone lactylation	144
Mapping the peripheral immune landscape of Parkinson’s disease patients with single-cell sequencing	139
The vascular contribution of apolipoprotein E to Alzheimer’s disease	135
A data-driven study of Alzheimer's disease related amyloid and tau pathology progression	134

Dysfunction of the magnocellular subdivision of the visual thalamus in developmental dyslexia	134
Dopamine and the dynamics of subthalamic and leg muscle activities in parkinsonian stepping	129
Thalamostriatal disconnection underpins long-term seizure freedom in frontal lobe epilepsy surgery	123
Optogenetic stimulation of the superior colliculus suppresses genetic absence seizures	121
PET-MRI biomarkers reveal efficacy of a novel NLRP3 inhibitor in Parkinson’s disease models	117
The RAB3A hot spot variant R83W causes spasticity as part of the ataxia-spasticity spectrum	117
Deep brain stimulation: a tale of two targets … and closing the loop	115
The use of optical coherence tomography in neurology: a review	115
From bugs to brain: unravelling the GABA signalling networks in the brain–gut–microbiome axis	113
Brain repair mechanisms after cell therapy for stroke	111
Clinical dimensions along the non-fluent variant primary progressive aphasia spectrum	108
Trigeminal nerve microstructure is linked with neuroinflammation and brainstem activity in migraine	106
Lesion correlates of impaired acoustic-phonetic perception after unilateral left hemisphere stroke	106
Gain-of-function and loss-of-function variants in GRIA3 lead to distinct neurodevelopmental phenotypes	101
Brain cholesterol and Alzheimer's disease: challenges and opportunities in probe and drug development	100
Dysregulated cortical excitability and tau phosphorylation in a β3 integrin mouse model of autism	99
Speech and language markers of neurodegeneration: a call for global equity	99
Integrative genomics reveals pathogenic mediator of valproate-induced neurodevelopmental disability	98
Correction to: New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy	98
Stuttering associated with a pathogenic variant in the chaperone protein cyclophilin 40	97
Cytotoxic T cells and plasma cells dominate early in temporal lobe epilepsy with GAD antibodies	96
Demystifying interictal discharges and seizure initiation in focal epilepsy	96
Reply: Unblinding in the lecanemab trial in Alzheimer’s disease	93
Synaptic dysregulation in a mouse model of GRIN2D developmental and epileptic encephalopathy	91
Multiple sclerosis in Denmark (1950–2023): mean age, sex distribution, incidence and prevalence	89
Natural experiment on neuroinflammatory disease incidence and infection links pre- and post-COVID-19	87
Routes of precursors’ migration in remyelination	86
The three deceits of bureaucracy	85
How COVID-19 affects microvessels in the brain	84
New mechanistic insights into hereditary spastic paraplegias	83
Extra-cranial cholinergic lesions in dementia with Lewy bodies	83
Functional network reorganization precedes apathy in Parkinson’s disease: a neural marker of risk?	82
Loss-of-function variants inMYCBP2cause neurobehavioural phenotypes and corpus callosum defects	82
Preclinical type 2 diabetes mellitus subtypes: new insights into diabetes, depression and dementia	82
Distinct contribution of spinal neuropeptide Y and NPY1R neurons to morphine analgesia	77
Structural covariance analysis for neurodegenerative and neuroinflammatory brain disorders	77
Midbrain cytotoxic T cells as a distinct neuropathological feature of progressive supranuclear palsy	77
From phenomena to phrasing: rethinking seizure classification through history	76
Clinical and MRI measures to identify non-acute MOG-antibody disease in adults	76
The low dimensionality of post-stroke cognitive deficits: it’s the lesion anatomy!	76
Periventricular remyelination failure in multiple sclerosis: a substrate for neurodegeneration	76
Evolutionary perspectives on mRNA signatures of neurodegeneration-related brain remodelling	76
Biallelic null variants in PNPLA8 cause microcephaly by reducing the number of basal radial glia	76
Multifaceted nanoparticles: emerging mechanisms and therapies in neurodegenerative diseases	75
Disruption of DNA methylation underpins the neuroinflammation induced by targeted CNS radiotherapy	73
Multiple lines of evidence for disruption of nuclear lamina and nucleoporins in FUS amyotrophic lateral sclerosis	73
Deciphering the impact of coding and non-coding SCN1A gene variants on RNA splicing	73
Multimodal mapping of regional brain vulnerability to focal cortical dysplasia	72
A sensory neuron-specific long non-coding RNA reduces neuropathic pain by rescuing KCNN1 expression	71
Clinical features and prognostic factors in adults with brain abscess	71

Molecular and clinical spectrum of epilepsy-dyskinesia syndromes: a cross-sectional study of 609 patients	71
Rigidity in Parkinson’s disease	69
Genome-wide association study of neuropathological features in Lewy body disease	68
Normalization of network activity in an epilepsy model with a constitutively active GABBR2 variant	68
Treatment-resistant recurrent unipolar and bipolar depression: associative learning abnormalities	68
The interictal suppression hypothesis is the dominant differentiator of seizure onset zones in focal epilepsy	68
Plasma pTau 217/β-amyloid 1–42 ratio for enhanced accuracy and reduced uncertainty in detecting amyloid pathology	68
Long-term neuropsychological trajectories in children with epilepsy: does surgery halt decline?	68
Integrative miRNA–mRNA profiling of human epidermis: unique signature of SCN9A painful neuropathy	67
Loss of DOT1L disrupts neuronal transcription and leads to a neurodevelopmental disorder	67
That which we call cortisol awakening response, by any other word would smell as sweet	66
Cortical cerebral microinfarcts spark cognitive decline	66
GGC repeat expansions in NOTCH2NLC cause uN2CpolyG cerebral amyloid angiopathy	65
Cross-seeding by prion protein inactivates TDP-43	65
Defective lipid signalling caused by mutations inPIK3C2Bunderlies focal epilepsy	64
Biallelic LGI1 and ADAM23 variants cause hippocampal epileptic encephalopathy via the LGI1–ADAM22/23 pathway	64
Extracellular vesicle biomarkers for complement dysfunction in schizophrenia	64
A generalizable data-driven model of atrophy heterogeneity and progression in memory clinic settings	63
Multicentre analysis of seizure outcome predicted by removal of high-frequency oscillations	63
Is glymphatic clearance the secret to restorative sleep?	63
Neural stem cell therapies for spinal cord injury repair: an update on recent preclinical and clinical advances	63
How modular are modules in visual cortex?	62
Novel insight into TRPV1-induced mitochondrial dysfunction in neuropathic pain	62
Activation and sensitization of meningeal nociceptors by PACAP-38: implications for migraine headache	62
Hippocampal synaptic failure is an early event in experimental parkinsonism with subtle cognitive deficit	62
Correction to: Sex-specific modulation of amyloid-β on tau phosphorylation underlies faster tangle accumulation in females	61
From shadows to spotlight: the evolution of migraine stigma since the 17th century	61
Correction to: Blood–brain barrier opening of the default mode network in Alzheimer's disease with magnetic resonance-guided focused ultrasound	60
Correction to: Remyelination of chronic demyelinated lesions with directly induced neural stem cells	60
A novel eye-movement impairment in multiple sclerosis indicating widespread cortical damage	59
Multicompartmental models and diffusion abnormalities in paediatric mild traumatic brain injury	59
Widespread white matter oedema in subacute COVID-19 patients with neurological symptoms	58
Large-scale rare variant burden testing in Parkinson's disease	58
Failure of C9orf72 sense repeat-targeting antisense oligonucleotides: lessons learned and the path forward	58
The use of animals in neuroscience research	58
Reply: Do we need new MRI criteria for the diagnosis of radiologically isolated syndrome?	57
Untangling white matter fibre changes in Alzheimer's disease and small vessel disease	57
Endosomal 2Cl−/H+ exchangers regulate neuronal excitability by tuning Kv7/KCNQ channel density	57
Neuromelanin as a nidus for neurodegeneration	57
Correction to: Expanded clinical phenotype spectrum correlates with variant function in SCN2A-related disorders	57
Reply: The correlation of behavioural deficits post-stroke: a trivial issue?	57
A journey towards the pot of gold	57
Occludin modulates HIV and ischaemic stroke response via the mitochondrial antiviral signalling pathway	56
Role of CD5 signalling for pro-inflammatory Th17 response in multiple sclerosis	56
Reduced striatal dopamine transmission as a transdiagnostic substrate of psychomotor retardation	56
JC virus spread is potentiated by glial replication and demyelination-linked glial proliferation	56
Reply: Lecanemab: turning point, or status quo? An ethics perspective	55
Distinct cerebellar networks underpin clinical improvement in adolescent Tourette disorder	55
Sleep and seizure risk in epilepsy: bed and wake times are more important than sleep duration	55
Common and distinct fronto-striatal volumetric changes in heroin and cocaine use disorders	55
Anatomo-functional basis of emotional and motor resonance elicited by facial expressions	55
The human subthalamic nucleus transiently inhibits active attentional processes	54
White matter connections within the central sulcus subserving the somato-cognitive action network	54
Effort avoidance as a core mechanism of apathy in frontotemporal dementia	54
In silico versus functional characterization of genetic variants: lessons from muscle channelopathies	54
Interferon-γ controls aquaporin 4-specific Th17 and B cells in neuromyelitis optica spectrum disorder	54
The lysosomal β-glucocerebrosidase strikes mitochondria: implications for Parkinson’s therapeutics	53
Age-related and amyloid-beta-independent tau deposition and its downstream effects	53
Early onset hereditary neuronopathies: an update on non-5qmotor neuron diseases	53
Estimating the time course of biomarker changes in Alzheimer’s disease	53
Plasma VEGFA and PGF impact longitudinal tau and cognition in preclinical Alzheimer’s disease	53
Cdc42GAP deficiency contributes to the Alzheimer’s disease phenotype	52
Impaired value-based decision-making in Parkinson’s disease apathy	52
Basal forebrain integrity, cholinergic innervation and cognition in idiopathic Parkinson’s disease	52
Delineation of functionally essential protein regions for 242 neurodevelopmental genes	52
Decoding inflammatory pathways in spinal muscular atrophy: implications for next-generation therapies	52
Amyloid-β predominant Alzheimer’s disease neuropathologic change	52
Neural basis of speech and grammar symptoms in non-fluent variant primary progressive aphasia spectrum	52
Imaging chronic active lesions in multiple sclerosis: a consensus statement	51
Nigrostriatal tau pathology in parkinsonism and Parkinson’s disease	51
Misdirected yet intact TREX1 exonuclease activity causes human cerebral and systemic small vessel disease	51
Genetic variability in sporadic amyotrophic lateral sclerosis	51
Is it time to rename hereditary cases of cerebral palsy?	51
Localizing epileptogenic tissues in epilepsy: are we losing (the) focus?	50
A foothold in detection of limbic-predominant age-related TDP-43 encephalopathy	50
Interleukin-17B is a new biomarker of human muscle regeneration in dystrophinopathies	50
Tiam1 is part of a novel mechanism for morphine tolerance and hyperalgesia	50
Understanding brain calcification via N-terminal acetylation at the Golgi apparatus	49
Correction to: Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates	49
Bridging the gaps between JCV infection models and human disease	49

Shedding light on a novel circuit within primary motor cortex as a target for neuromodulation	49
The ‘secret connections’ of the brain: a connectomic reserve for neuroplasticity?	48
The visual cortex in the blind but not the auditory cortex in the deaf becomes multiple-demand regions	48
Four dimensions of naturalistic language production in aphasia after stroke	48
Surgical white matter disruption leads to downstream atrophy in the non-resected human brain	48
Biomarker evidence of neurodegeneration in mid-life former rugby players	47
Sleep circuit modulation: from animal models to human translation	47
USP25 in genetic generalized epilepsy: a gene under scrutiny	47
Cul-4 inhibition rescues spastin levels and reduces defects in hereditary spastic paraplegia models	47
Synaptic and cognitive impairment associated with L444P heterozygous glucocerebrosidase mutation	47
Precision dynamics of predictive coding in functional neurological disorder	47
Motor compensation in Parkinson’s disease: an empirical challenge with clinical implications	47
CGRP signalling in migraine: time to look downstream?	46
Thalamic stereo-EEG in epilepsy surgery: where do we stand?	46
HDAC6 regulates BACE1 stability and NLRP3 inflammasome activation in Alzheimer’s disease	46
Clinical and biochemical characterization of amyotrophic lateral sclerosis in a CHCHD10 R15L family	46
Brain accumulation of lactosylceramide characterizes GALC deficiency in a zebrafish model of Krabbe disease	46
Alzheimer proteopathic tau seeds are biochemically a forme fruste of mature paired helical filaments	45
ZSCAN10 deficiency causes a neurodevelopmental disorder with characteristic oto-facial malformations	45
Elucidating the nociceptive role of CGRP in migraine headache	45
Imaging progenitor cell differentiation during central nervous system remyelination using an MRI gene reporter	45
Comparative transcriptomics reveal molecular convergence and divergence in parkinsonian disorders	45
Satellite glial GLRX3 drives ageing-biased neuropathic pain via HMGB1	44
Characterizing proteomic and transcriptomic features of missense variants in amyotrophic lateral sclerosis genes	44
Machine learning model based on plasma proteomics for the identification of Parkinson’s disease	44
Emotional bias modification weakens game-related compulsivity and reshapes frontostriatal pathways	44
The basal forebrain cholinergic system as target for cell replacement therapy in Parkinson’s disease	44
Interpretable surface-based detection of focal cortical dysplasias: a Multi-centre Epilepsy Lesion Detection study	43
PTPA variants and the risk for Parkinson’s disease in diverse ancestry populations	43
Morc2a variants cause hydroxyl radical-mediated neuropathy and are rescued by restoring GHKL ATPase	43
Targeting glutamatergic pathways: genetic insights into comorbid neurodevelopmental disorders	43
C-terminal TMEM106B fragments in human brain correlate with disease-associated TMEM106B haplotypes	43
Seeding, maturation and propagation of amyloid β-peptide aggregates in Alzheimer’s disease	43
Ageing and remyelination failure in people with multiple sclerosis	43
Amyloid-β-activated microglia can induce compound proteinopathies	43
Multimodal multicentre investigation of diagnostic and prognostic markers in disorders of consciousness	43
The functional role of the precuneus	43
Is SORL1 a common genetic target across neurodegenerative diseases? A multi-ancestry biobank study	42
Plasma biomarkers in chronic single moderate/severe traumatic brain injury	42
Reply: Putative benefits of vitamin D supplements in multiple sclerosis out of reach due to sample size	42
The ageing central nervous system in multiple sclerosis: the imaging perspective	42
Motor network gamma oscillations in chronic home recordings predict dyskinesia in Parkinson’s disease	42
Chasing MOG antibodies down … assays and lumbar punctures	42
Right temporal degeneration and socioemotional semantics: semantic behavioural variant frontotemporal dementia	42
Medial temporal lobe structural changes when Down syndrome and Alzheimer’s disease collide	42
Reply: Methodological drawbacks in the alleged association between foetal sonographic anomalies and autism	42
One transgene, two myopathies: an MTM1 ‘cross gene therapy’ for BIN1 deficiency?	41
TGFβ4 alleviates the phenotype of Charcot–Marie–Tooth disease type 1A	41
Reply: Neural substrates of the link between dual-task gait and dementia: an intermediary step in which direction?	40
Nifuroxazide rescues the deleterious effects due to CHCHD10-associated MICOS defects in disease models	40
Data-driven modelling of tau pathology reveals distinct progressive supranuclear palsy subtypes	40
Myelination potential and injury susceptibility of grey versus white matter human oligodendrocytes	40
The complexity of interpreting TSPO PET neuroimaging in first-episode psychosis	40
Increase of HCN current in SOD1-associated amyotrophic lateral sclerosis	40
Pure autonomic failure as an essential window into progression of synucleinopathies	40
Genome-wide epistasis analysis reveals significant epistatic signals associated with Parkinson’s disease risk	39
Expedited epilepsy surgery prior to drug resistance in children: a frontier worth crossing?	39
Uncovering the distinct macro-scale anatomy of dysexecutive and behavioural degenerative diseases	39
Reply: The challenge of assessing invasive biomarkers for epilepsy surgery and To plan efficacious epilepsy surgery	39
Connectivity as a universal predictor of tau progression in atypical Alzheimer’s disease	39
Noradrenergic alterations in Parkinson’s disease: a combined 11C-yohimbine PET/neuromelanin MRI study	39
Neurophysiological consequences of synapse loss in progressive supranuclear palsy	39
Great science does not communicate itself: but who should and how?	39
Phenotypic individual clusters and metabolic tuber subtypes refine surgical strategy in tuberous sclerosis complex	39
Reply: An epigenetic basis for genetic anticipation in facioscapulohumeral muscular dystrophy type 1	39
Brain essay competition winner on artificial general intelligence	39
Brainstem cavernous malformations: observation, microsurgical resection or stereotactic radiosurgery	39
Mitochondrial damage is associated with an early immune response in inclusion body myositis	38
Multimodal layer modelling reveals in vivo pathology in amyotrophic lateral sclerosis	38
Phenoconversion in pure autonomic failure: a multicentre prospective longitudinal cohort study	38
Motivational and cognitive predictors of apathy after subthalamic nucleus stimulation in Parkinson’s disease	38
Ligand-free mitochondria-localized mutant AR-induced cytotoxicity in spinal bulbar muscular atrophy	38
Intra-putaminal muscarinic receptor agonist infusion induces a dystonic phenotype in non-human primates	38
Cation leak through the ATP1A3 pump causes spasticity and intellectual disability	37
Sex-specific genetic drivers of memory, executive functioning and language in older adults	37
Dynamic reorganization of task-related network interactions in post-stroke aphasia recovery	37
Limitation of life sustaining therapy in disorders of consciousness: ethics and practice	37
Direct electrical brain stimulation of human memory: lessons learnt and future perspectives	37
Efficacy of MEDI0618, a pH-dependent monoclonal antibody targeting PAR2, in preclinical models of migraine	37
Defining repetitive behaviours in frontotemporal dementia	37
Clinicopathological correlates in the frontotemporal lobar degeneration–motor neuron disease spectrum	37
Memory deficits of MDMA users are linked to cortical thinning related to 5-HT receptor densities	37
Oxytocin receptor neurons in the paraventricular thalamus as a nexus for social behaviour and fear	37
Dopamine and deep brain stimulation accelerate the neural dynamics of volitional action in Parkinson's disease	37
Clinical features and prognostic factors in adults with viral meningitis	37
Parkinson’s disease beyond the brain: erythrocyte α-synuclein transfer across the blood–brain barrier	37
Mitochondrial dynamics and bioenergetics in Alzheimer’s induced pluripotent stem cell-derived neurons	36
Cerebellar pathology contributes to neurodevelopmental deficits in spinal muscular atrophy	36
The Wernicke conundrum revisited: evidence from connectome-based lesion-symptom mapping	36
Role of pattern recognition receptors in chemotherapy-induced neuropathic pain	36
Interaction of motor behaviour, cortical oscillations and deep brain stimulation in Parkinson’s disease	36
Correction to: TMEM63C mutations cause mitochondrial morphology defects and underlie hereditary spastic paraplegia	36
Genome-wide contribution of common short-tandem repeats to Parkinson’s disease genetic risk	36
Who am I?	36
An alternative therapeutic approach to haematopoetic stem cell transplantation in early cerebral adrenoleukodystrophy	36